BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation

Reuters

Jan 12

BRIEF-<a href="https://laohu8.com/S/HRMY">Harmony Biosciences</a> Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation

Jan 12 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:

HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATION
HARMONY BIOSCIENCES Q4 PRELIM UNAUDITED NET PRODUCT REVENUE $243 MILLION
HARMONY BIOSCIENCES: WAKIX NET REVENUE PROJECTED BETWEEN $1.0 BILLION - $1.04 BILLION FOR 2026

Source text: ID:nBw7PrSsza

Further company coverage: HRMY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602510412"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602510412\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602510412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602510412","market":"nz","top_or_hot":-1,"title":"BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Harmony Biosciences Holdings Inc <span>HRMY.O</span>:</p><ul><li><p>HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATION</p></li><li><p>HARMONY BIOSCIENCES Q4 PRELIM UNAUDITED NET PRODUCT REVENUE $243 MILLION</p></li><li><p>HARMONY BIOSCIENCES: WAKIX NET REVENUE PROJECTED BETWEEN $1.0 BILLION - $1.04 BILLION FOR 2026</p></li></ul><p>Source text: <span>ID:nBw7PrSsza</span></p><p>Further company coverage: <span>HRMY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HRMY\">Harmony Biosciences</a> Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Harmony Biosciences Holdings Inc <span>HRMY.O</span>:</p><ul><li><p>HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATION</p></li><li><p>HARMONY BIOSCIENCES Q4 PRELIM UNAUDITED NET PRODUCT REVENUE $243 MILLION</p></li><li><p>HARMONY BIOSCIENCES: WAKIX NET REVENUE PROJECTED BETWEEN $1.0 BILLION - $1.04 BILLION FOR 2026</p></li></ul><p>Source text: <span>ID:nBw7PrSsza</span></p><p>Further company coverage: <span>HRMY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SU:1","article_id":"2602510412","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602510412","pubTimestamp":1768223630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value CreationJan 12 (Reuters) - Harmony Biosciences Hold","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc.","BK4007":"制药"},"translate_title":"简介-Harmony Biosciences引导Wakix投资超过10亿美元®2026年收入推进强大的后期管道，具有长期价值创造潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":0.9},"content_text":"BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value CreationJan 12 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATIONHARMONY BIOSCIENCES Q4 PRELIM UNAUDITED NET PRODUCT REVENUE $243 MILLIONHARMONY BIOSCIENCES: WAKIX NET REVENUE PROJECTED BETWEEN $1.0 BILLION - $1.04 BILLION FOR 2026Source text: ID:nBw7PrSszaFurther company coverage: HRMY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}